LymPro has been validated by Beckton Dickenson. Their name was on the posters presented in Copenhagen. LymPro's validity can't get a better endorsement than that!
All the diagnostic experts that have come to help launch LymPro would not have come unless they knew it was the real deal.
Loco, I don't think you understand the whole univariant/multivariant difference yet. You need to get it before this "bridge data" is released this week, because it will be about univariant biomarkers.
The Pharmas doing AD clinical trials now on thousands of patients are using a screening tool that is far more expensive than LymPro and only about 80% accurate. LymPro's univariant CD 19 biomarkder is 80% accurate on a stand alone basis. Pluse, it is 30 to 40% cheaper and super easy to use.
If a Pharma wants to use all 6 univariant biomarkers and apply some complex math to come up with 95% accuracy, they can do that. But what Gerald told us is that from his conversations with the Pharmas doing AD trials....they were fine with the ease and cheapness of the 80% CD 19 all by itself!!
AMBS shareholders simply got fixated on the multivariant numbers in the 90s, and because most of us aren't diagnostic experts and are unfamiliar with what actually goes on in these AD trials....we think the univariant numbers are inferior. We've got to grow up!! We got a double whammy in July because we got pumped and dumped by Money Runners, who doubled the pain we experienced when all the data we were waiting for wasn't ready. Plus, the incomplete data we got was univariant instead of the multivariant that we were expecting.
July was a disaster! But get over it everyone!!!
Joe Rubenfeld was right. "We are launching a diagnostic in 3.5 months! We're there." The univariant LP002 data we get this week will lay the foundation for the validation study ICON will complete early December where we'll finally get the multivariant data, prior to commercializing.
Pharmas doing AD trials will eat up Lympro and our revenue stream will grow handsomely for the next decade....if the diagnostic company isn't bought out first for a couple billion.
All the diagnostic experts that have come to help launch LymPro would not have come unless they knew it was the real deal.
Loco, I don't think you understand the whole univariant/multivariant difference yet. You need to get it before this "bridge data" is released this week, because it will be about univariant biomarkers.
The Pharmas doing AD clinical trials now on thousands of patients are using a screening tool that is far more expensive than LymPro and only about 80% accurate. LymPro's univariant CD 19 biomarkder is 80% accurate on a stand alone basis. Pluse, it is 30 to 40% cheaper and super easy to use.
If a Pharma wants to use all 6 univariant biomarkers and apply some complex math to come up with 95% accuracy, they can do that. But what Gerald told us is that from his conversations with the Pharmas doing AD trials....they were fine with the ease and cheapness of the 80% CD 19 all by itself!!
AMBS shareholders simply got fixated on the multivariant numbers in the 90s, and because most of us aren't diagnostic experts and are unfamiliar with what actually goes on in these AD trials....we think the univariant numbers are inferior. We've got to grow up!! We got a double whammy in July because we got pumped and dumped by Money Runners, who doubled the pain we experienced when all the data we were waiting for wasn't ready. Plus, the incomplete data we got was univariant instead of the multivariant that we were expecting.
July was a disaster! But get over it everyone!!!
Joe Rubenfeld was right. "We are launching a diagnostic in 3.5 months! We're there." The univariant LP002 data we get this week will lay the foundation for the validation study ICON will complete early December where we'll finally get the multivariant data, prior to commercializing.
Pharmas doing AD trials will eat up Lympro and our revenue stream will grow handsomely for the next decade....if the diagnostic company isn't bought out first for a couple billion.
